SVA
Sinovac Biotech Ltd
NASDAQ: SVA · HEALTHCARE · BIOTECHNOLOGY
$6.47
+0.00% today
Updated 2026-06-05
Market cap
$642.44M
P/E ratio
6.66
P/S ratio
1.83x
EPS (TTM)
$0.97
Dividend yield
850.00%
52W range
$6 – $6
Volume
—
WallStSmart proprietary scores
80
out of 100
Grade: A
Strong Buy
Investment rating
7.3
Growth
B+8.5
Quality
A7.0
Profitability
B+5.7
Valuation
C+3/9
Piotroski F-Score
Weak
6.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$3.52
-45.60%
12-Month target
$8.08
+24.88%
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Altman Z 6.08 — safe zone
+ Profit margin 21.60% — above average
+ Free cash flow $93.26M — positive
+ Revenue growth 303.70% QoQ
+ Debt/equity 0.04x — low leverage
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2020 | 2021 | 2022 | 2023 | TTM |
|---|---|---|---|---|---|
| Revenue | $510.62M | $19.37B | $1.49B | $448.27M | $510.62M |
| Net income | $110.37M | $8.47B | $113.87M | $-99.92M | $-116.84M |
| EPS | — | — | — | — | $0.97 |
| Free cash flow | $351.66M | $14.63B | $-1.17B | $-39.67M | $93.26M |
| Profit margin | 21.61% | 43.70% | 7.63% | -22.29% | 21.60% |
Peer comparison
Smart narrative
Sinovac Biotech Ltd trades at $6.47. representing a P/E of 6.66x trailing earnings. Our Smart Value Score of 80/100 indicates the stock is excellent. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 6.08, it sits in the safe zone. TTM revenue stands at $510.62M. with profit margins at 21.60%.
Frequently asked questions
What is Sinovac Biotech Ltd's stock price?
Sinovac Biotech Ltd (SVA) trades at $6.47, on a P/E of 6.7x and a P/S of 1.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Sinovac Biotech Ltd overvalued?
Sinovac Biotech Ltd carries a Smart Value Score of 80/100 (Grade A), which we rate Strong Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Sinovac Biotech Ltd (SVA)?
The 12-month analyst consensus target is $3.52, about 45.6% below the current $6.47. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of SVA by 2030?
Our research-backed model puts the 2030 base case at $12.63, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Sinovac Biotech Ltd's revenue?
Sinovac Biotech Ltd's trailing twelve-month revenue is $510.62M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Sinovac Biotech Ltd's Altman Z-Score is 6.08, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryChina
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.83x
ROE-6.42%
Beta0.07
50D MA$6.47
200D MA$6.47
Shares out0.10B
Float0.06B
Short ratio—
Avg volume—
Performance
1 week+0.00%
1 month+0.00%
3 months+0.00%
YTD+0.00%
1 year—
3 years—
5 years—